Aegerion Pharmaceuticals Sets New 52-Week Low at $28.86 (AEGR)
Aegerion Pharmaceuticals (NASDAQ:AEGR) hit a new 52-week low on Tuesday , AnalystRatingsNetwork.com reports. The company traded as low as $28.86 and last traded at $28.93, with a volume of 566,577 shares trading hands. The stock had previously closed at $30.94.
AEGR has been the subject of a number of recent research reports. Analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock. Separately, analysts at Citigroup Inc. downgraded shares of Aegerion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 7th. Finally, analysts at Deutsche Bank cut their price target on shares of Aegerion Pharmaceuticals from $115.00 to $70.00 in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $74.45.
The stock’s 50-day moving average is $32.88 and its 200-day moving average is $48.42. The company’s market cap is $852.3 million.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.35) by $0.10. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $33.58 million. On average, analysts predict that Aegerion Pharmaceuticals will post $-0.94 earnings per share for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.